AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26916685 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart 3 times daily + insulin detemir once daily
Number of subjects: 412
Study 26916685 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir alone once daily
Number of subjects: 412
Study 25066329 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive positive pressure ventilation (NPPV) for at least 12 months
Number of subjects: 195
Study 25066329 — intervention group
Group type: COMPARATOR
Intervention: Optimised standard treatment (control group)
Number of subjects: 195
Study 25066329 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV
Number of subjects: 195
Study 23043637 — intervention group
Group type: EXPERIMENTAL
Intervention: nano-formulated diclofenac 35 mg
Number of subjects: 202
Study 23043637 — intervention group
Group type: EXPERIMENTAL
Intervention: nano-formulated diclofenac 18 mg
Number of subjects: 202
Study 23043637 — intervention group
Group type: EXPERIMENTAL
Intervention: celecoxib 400 mg
Number of subjects: 202
Study 23043637 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 202
Study 19653748 — intervention group
Group type: EXPERIMENTAL
Intervention: Distractors presented in a rapid serial visual presentation stream
Number of subjects: 0
Study 19653748 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal presentation of distractors
Number of subjects: 0
Study 19653748 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprathreshold level presentation of the second target
Number of subjects: 0
Study 17610024 — intervention group
Group type: EXPERIMENTAL
Intervention: Open anterior approach
Number of subjects: 160
Study 17610024 — intervention group
Group type: EXPERIMENTAL
Intervention: Open preperitoneal approach
Number of subjects: 160
Study 17610024 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic transabdominal preperitoneal approach
Number of subjects: 160
Study 17610024 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic total extraperitoneal approach
Number of subjects: 160
Study 17610024 — intervention group
Group type: EXPERIMENTAL
Intervention: Open posterior approach
Number of subjects: 160
Study 15133754 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide GITS AM (5-20 mg)
Number of subjects: 42
Study 15133754 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide GITS PM (5-20 mg)
Number of subjects: 42
Study 15133754 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (5-20 mg)
Number of subjects: 42
Study 15133754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 12866726 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive analgesia (100 mg iv tramadol before induction of anesthesia)
Number of subjects: 90
Study 12866726 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive analgesia (100 mg iv tramadol immediately after peritoneal closure)
Number of subjects: 90
Study 12866726 — intervention group
Group type: COMPARATOR
Intervention: Control (100 mg iv tramadol immediately after operation)
Number of subjects: 90
Study 9846420 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral
Number of subjects: 188
Study 9846420 — intervention group
Group type: COMPARATOR
Intervention: Sandimmune
Number of subjects: 188
Study 7732668 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton-boll pectin (1 g per 100 ml of infant milk or food, 3 times a day for 45-60 days)
Number of subjects: 156
Study 7732668 — intervention group
Group type: COMPARATOR
Intervention: Control group (60 babies with identical diets but without pectin)
Number of subjects: 156
Study 813120 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 28
Study 813120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 31705729 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT imaging at 1 week post-primary radiochemotherapy (PET/CT2)
Number of subjects: 54
Study 31705729 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT imaging at 3 months post-primary radiochemotherapy (PET/CT3)
Number of subjects: 54
Study 31705729 — intervention group
Group type: EXPERIMENTAL
Intervention: PET/CT2
Number of subjects: 54
Study 30968110 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholera vaccine (OCV)
Number of subjects: 267270
Study 28711582 — intervention group
Group type: EXPERIMENTAL
Intervention: SM04690 0.03 mg
Number of subjects: 61
Study 28711582 — intervention group
Group type: EXPERIMENTAL
Intervention: SM04690 0.07 mg
Number of subjects: 61
Study 28711582 — intervention group
Group type: EXPERIMENTAL
Intervention: SM04690 0.23 mg
Number of subjects: 61
Study 28711582 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 61
Study 25981699 — intervention group
Group type: EXPERIMENTAL
Intervention: BOA‐RC2 prediction model
Number of subjects: 2680
Study 23357844 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 200 mg/lidocaine 1% (i.m.) given twice monthly
Number of subjects: 32
Study 23357844 — intervention group
Group type: COMPARATOR
Intervention: Clodronate 100 mg/lidocaine 1% (i.m.) given weekly
Number of subjects: 32
Study 23357844 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 32
Study 19779464 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs (various classes)
Number of subjects: 102
Study 16450155 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg hydrochlorothiazide (HCT)
Number of subjects: 103
Study 16450155 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg hydrochlorothiazide (HCT)
Number of subjects: 103
Study 15016019 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus tetracycline (TE) fibres
Number of subjects: 19
Study 15016019 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 19
Study 10368203 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernosal PGE1 (20 microg)
Number of subjects: 60
Study 10368203 — intervention group
Group type: COMPARATOR
Intervention: MUSE (1 mg)
Number of subjects: 60
Study 8874308 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose epinephrine (0.2 mg/kg)
Number of subjects: 30
Study 8874308 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose epinephrine (0.02 mg/kg)
Number of subjects: 30
Study 1503326 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparinoid (ORG 10172), 750 anti-factor Xa units twice daily
Number of subjects: 87
Study 1503326 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin, 5000 units subcutaneously twice daily
Number of subjects: 87
Study 1503326 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparinoid (ORG 10172)
Number of subjects: 87
Study 1503326 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 87
Study 1503326 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 87
Study 6484216 — intervention group
Group type: EXPERIMENTAL
Intervention: CL115,574 (750 micrograms)
Number of subjects: 8
Study 6484216 — intervention group
Group type: EXPERIMENTAL
Intervention: CL115,574
Number of subjects: 8
Study 30424980 — intervention group
Group type: EXPERIMENTAL
Intervention: mHELP protocols (early mobilization, oral and nutritional assistance, and orienting communication) administered daily with usual care by a trained nurse until hospital discharge
Number of subjects: 377
Study 30424980 — intervention group
Group type: EXPERIMENTAL
Intervention: mHELP protocols
Number of subjects: 377
Study 30424980 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care only)
Number of subjects: 377
Study 30658375 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sodium fluoride varnish (Acclean Fluoride Varnish)
Number of subjects: 22
Study 30658375 — intervention group
Group type: COMPARATOR
Intervention: 3% oxalic acid/potassium salt solution (Super Seal Desensitizer)
Number of subjects: 22
Study 27600167 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential Immersive Life Skills (RILS) program (Group A)
Number of subjects: 30
Study 27600167 — intervention group
Group type: COMPARATOR
Intervention: Deferred RILS control group (Group B)
Number of subjects: 30
Study 27600167 — intervention group
Group type: COMPARATOR
Intervention: Non-residential life skills program (Group C)
Number of subjects: 30
Study 27600167 — intervention group
Group type: COMPARATOR
Intervention: Control group matched on age, diagnoses, and cognitive capacity not receiving any life skills intervention (Group D)
Number of subjects: 30
Study 24239799 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model for any medical complications
Number of subjects: 1476
Study 24239799 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model for major medical complications
Number of subjects: 1476
Study 23775972 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem-cell transplantation (HSCT)
Number of subjects: 208
Study 23775972 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 208
Study 23775972 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT
Number of subjects: 208
Study 20345274 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 0
Study 20345274 — intervention group
Group type: EXPERIMENTAL
Intervention: Galdakao-modified supine Valdivia position
Number of subjects: 0
Study 20345274 — intervention group
Group type: COMPARATOR
Intervention: Prone position
Number of subjects: 0
Study 18196225 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod (5 mg single dose) + Atenolol (50 mg once daily for 5 days)
Number of subjects: 25
Study 18196225 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod (5 mg single dose) + Diltiazem (240 mg once daily for 5 days)
Number of subjects: 25
Study 18196225 — intervention group
Group type: COMPARATOR
Intervention: Fingolimod alone
Number of subjects: 25
Study 15736778 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine porous bone mineral (BPBM), guided tissue regeneration (GTR), and platelet-rich plasma (PRP)
Number of subjects: 28
Study 15736778 — intervention group
Group type: COMPARATOR
Intervention: Open-flap debridement
Number of subjects: 28
Study 12953276 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral transplantation with one donor per side
Number of subjects: 34
Study 12953276 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral transplantation with four donors per side
Number of subjects: 34
Study 12953276 — intervention group
Group type: COMPARATOR
Intervention: Placebo procedure
Number of subjects: 34
Study 12953276 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment effect
Number of subjects: 34
Study 12953276 — intervention group
Group type: COMPARATOR
Intervention: Four-donor group vs. placebo
Number of subjects: 34
Study 12953276 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratification based on disease severity
Number of subjects: 34
Study 12953276 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplanted patients
Number of subjects: 34
Study 12953276 — intervention group
Group type: EXPERIMENTAL
Intervention: Striatal fluorodopa uptake
Number of subjects: 34
Study 10962136 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 200 mg/day for 10 days/month
Number of subjects: 0
Study 10962136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8664131 — intervention group
Group type: COMPARATOR
Intervention: 3 weekly regimen of cisplatin 60 mg m‐2 i.v. on day 1 and etoposide 120 mg m‐2 i.v. on day 1 and 100 mg b.d. orally on days 2 and 3 alternating with cyclophosphamide 600 mg m‐2 i.v., doxorubicin 50 mg m‐2 i.v. and vincristine 2 mg i.v. all on day 1 for a maximum of six courses (3 weekly)
Number of subjects: 167
Study 8664131 — intervention group
Group type: EXPERIMENTAL
Intervention: 10/11 day regimen with the same drugs but with each course consisting of half the 3 weekly dose given every 10 or 11 days for a maximum of 12 courses
Number of subjects: 167
Study 8664131 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measured using a daily diary card (DDC)
Number of subjects: 167
Study 1839902 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (mean dose 25 mg/day)
Number of subjects: 33
Study 1839902 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (mean dose 200 mg/day)
Number of subjects: 33
Study 1839902 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone/Metoprolol combination (logroton)
Number of subjects: 33
Study 1839902 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 33
Study 6340079 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 40
Study 6340079 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 40
Study 31964369 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascination 2 ceramic brackets
Number of subjects: 60
Study 31964369 — intervention group
Group type: COMPARATOR
Intervention: Pearl ceramic brackets
Number of subjects: 60
Study 31403221 — intervention group
Group type: EXPERIMENTAL
Intervention: Senior managers' awareness of sun safety policies
Number of subjects: 68
Study 31403221 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased communication about sun safety to employees
Number of subjects: 68
Study 28914355 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet CPAP device
Number of subjects: 170
Study 28914355 — intervention group
Group type: COMPARATOR
Intervention: Bubble CPAP device
Number of subjects: 170
Study 27899094 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised website experience combining shared stories, education, personal goal setting, and links to resources.
Number of subjects: 0
Study 27899094 — intervention group
Group type: EXPERIMENTAL
Intervention: Online feedback and semi-structured interviews during follow-up.
Number of subjects: 0
Study 24418244 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (6 g)
Number of subjects: 15
Study 24418244 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 g cornstarch)
Number of subjects: 15
Study 22157229 — intervention group
Group type: EXPERIMENTAL
Intervention: CD‐5As
Number of subjects: 110
Study 22157229 — intervention group
Group type: EXPERIMENTAL
Intervention: CM‐Lite
Number of subjects: 110
Study 22157229 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 110
Study 20923557 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (10% w/v) dental coating
Number of subjects: 983
Study 20923557 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 983
Study 18398664 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized educational session and 1 pack of EC
Number of subjects: 446
Study 18398664 — intervention group
Group type: COMPARATOR
Intervention: Control group education about periconception folate supplementation
Number of subjects: 446
Study 16000612 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy with two cycles of carboplatin and paclitaxel
Number of subjects: 0
Study 16000612 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy
Number of subjects: 0
Study 16000612 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation chemotherapy
Number of subjects: 0
Study 12800728 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-containing milk (240 mL daily for 14 days)
Number of subjects: 30
Study 12800728 — intervention group
Group type: COMPARATOR
Intervention: Lactose-hydrolyzed milk (240 mL daily for 14 days)
Number of subjects: 30
Study 10483329 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (200 mg three times daily)
Number of subjects: 287
Study 10483329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study 8354803 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolytic therapy with either streptokinase or recombinant tissue-type plasminogen activator within 7 hours of symptom onset (mean 4.8 hours)
Number of subjects: 132
Study 8354803 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolytic therapy
Number of subjects: 132
Study 3523590 — intervention group
Group type: EXPERIMENTAL
Intervention: First screen mammography
Number of subjects: 23101
Study 28563974 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtrum A6 TouchCare® CGM System
Number of subjects: 63
Study 26613636 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength-based case management intervention (CMI)
Number of subjects: 75
Study 26613636 — intervention group
Group type: COMPARATOR
Intervention: Referral only
Number of subjects: 75
Study 26122891 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly sessions at the start of CBT
Number of subjects: 200
Study 26122891 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly sessions at the start of IPT
Number of subjects: 200
Study 26122891 — intervention group
Group type: COMPARATOR
Intervention: Once-weekly sessions at the start of CBT
Number of subjects: 200
Study 26122891 — intervention group
Group type: COMPARATOR
Intervention: Once-weekly sessions at the start of IPT
Number of subjects: 200
Study 22798280 — intervention group
Group type: EXPERIMENTAL
Intervention: Written Asthma Action Plan (WAAP)
Number of subjects: 80
Study 22798280 — intervention group
Group type: COMPARATOR
Intervention: Verbal counseling
Number of subjects: 80
Study 22088518 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 - 120 mg
Number of subjects: 210
Study 22088518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 19245384 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse case-managed approach (NCMIT)
Number of subjects: 865
Study 19245384 — intervention group
Group type: COMPARATOR
Intervention: Standard programmes with tracking (SIT)
Number of subjects: 865
Study 19245384 — intervention group
Group type: COMPARATOR
Intervention: Standard programmes without tracking (SI)
Number of subjects: 865
Study 17003569 — intervention group
Group type: EXPERIMENTAL
Intervention: cilazapril for 8 weeks
Number of subjects: 24
Study 17003569 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan for 8 weeks
Number of subjects: 24
Study 15259448 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibition (abciximab) in addition to dalteparin (subcutaneous)
Number of subjects: 7800
Study 15259448 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (subcutaneous)
Number of subjects: 7800
Study 15259448 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of NT-proBNP and creatinine clearance
Number of subjects: 7800
Study 15259448 — intervention group
Group type: EXPERIMENTAL
Intervention: Any detectable elevation of TnT and reduced creatinine clearance
Number of subjects: 7800
Study 15259448 — intervention group
Group type: COMPARATOR
Intervention: Aspirin and heparin (or dalteparin)
Number of subjects: 7800
Study 11145323 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 163
Study 11145323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 9824526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory utilization review (UR)
Number of subjects: 41
Study 9824526 — intervention group
Group type: COMPARATOR
Intervention: No ambulatory utilization review (Control)
Number of subjects: 41
Study 9824526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory utilization review (UR) after 4 weeks without participation
Number of subjects: 41
Study 8062320 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide nasal aerosol (110, 220, or 440 micrograms)
Number of subjects: 93
Study 2738596 — intervention group
Group type: EXPERIMENTAL
Intervention: Social work intervention (regular visits by a research social worker over 4 months)
Number of subjects: 44
Study 2738596 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined results from both groups
Number of subjects: 44
Study 31909725 — intervention group
Group type: EXPERIMENTAL
Intervention: iCBT‐I (internet-delivered cognitive behavioral therapy for insomnia)
Number of subjects: 177
Study 30975977 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (SSRI) preceded by pindolol (5-HT1AR antagonist)
Number of subjects: 23
Study 30975977 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 23
Study 30975977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 28540436 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral melatonin (0.5 mg/kg, max 20 mg)
Number of subjects: 80
Study 28540436 — intervention group
Group type: COMPARATOR
Intervention: Oral midazolam (0.5 mg/kg, max 20 mg)
Number of subjects: 80
Study 26529076 — intervention group
Group type: EXPERIMENTAL
Intervention: 23vPPV vaccine administered during pregnancy (at 30-36 weeks gestation)
Number of subjects: 227
Study 26529076 — intervention group
Group type: EXPERIMENTAL
Intervention: 23vPPV vaccine administered at birth
Number of subjects: 227
Study 26529076 — intervention group
Group type: COMPARATOR
Intervention: Control group (unvaccinated)
Number of subjects: 227
Study 26529076 — intervention group
Group type: EXPERIMENTAL
Intervention: 23vPPV vaccine during pregnancy (post-hoc analysis)
Number of subjects: 227
Study 23174369 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg/day
Number of subjects: 42
Study 23174369 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 42
Study 21540874 — intervention group
Group type: EXPERIMENTAL
Intervention: Mushroom group (28,000 IU vitamin D2 via experimental soup)
Number of subjects: 26
Study 21540874 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplement group (28,000 IU vitamin D2 via supplement)
Number of subjects: 26
Study 21540874 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 26
Study 18498956 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 0
Study 18498956 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 14566300 — intervention group
Group type: EXPERIMENTAL
Intervention: Coil occlusion of patent ductus arteriosus (PDA)
Number of subjects: 0
Study 14566300 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic variables
Number of subjects: 0
Study 10735923 — intervention group
Group type: EXPERIMENTAL
Intervention: LAO (lansoprazole 30 mg o.d., amoxycillin 1 g b.d., ornidazole 500 mg b.d.)
Number of subjects: 80
Study 10735923 — intervention group
Group type: COMPARATOR
Intervention: LAC (lansoprazole 30 mg o.d., amoxycillin 1 g b.d., clarithromycin 500 mg b.d.)
Number of subjects: 80